Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.
Phase:
PHASE1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
Institute for Integration of Medicine & Science-UT Health San Antonio